Optiray (Ioversol)

Ioversol works by providing a high concentration of iodine atoms that absorb X‑ray photons. When injected intravenously or intra‑arterially, it circulates through the vascular system and temporarily attenuates X‑rays, creating a contrast difference between blood‑filled structures and surrounding tissues. This contrast improves the delineation of anatomical features on radiographic and CT images.

The specific dose of Optiray is determined by the prescribing physician based on the type of imaging study, patient weight, renal function, and clinical protocol. Healthcare professionals calculate the appropriate volume to achieve optimal image quality while minimizing potential risks.

The safety of Optiray in pregnancy or while breastfeeding has not been definitively established. Use during pregnancy should be considered only if the diagnostic benefit outweighs potential risks, and the decision should be made by the treating physician. Breastfeeding mothers should consult their healthcare provider for guidance.

To order Optiray, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After receiving the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Optiray (ioversol) is a non‑ionic, low‑osmolality iodinated contrast agent, offering a favorable safety profile compared with older high‑osmolality agents. Compared with other low‑osmolality agents, ioversol provides comparable image quality and a similar incidence of mild adverse reactions, while maintaining a reduced risk of severe nephrotoxicity.

Optiray should be stored at ambient temperature, preferably below 25 °C. Keep the solution in its original container, protect it from direct sunlight, moisture, and extreme temperature fluctuations. Do not freeze the product, and ensure the vial is sealed until ready for use.

Optiray is administered by a qualified healthcare professional via intra‑arterial or intravenous injection, depending on the imaging procedure. The injection is typically performed using a power injector or manual bolus, following the specific protocol for the diagnostic study to achieve optimal contrast enhancement.

The most serious risks include severe allergic reactions (anaphylaxis), contrast‑induced nephropathy leading to acute kidney injury, hypotension or cardiovascular collapse, and rare pulmonary edema. Patients with known severe iodine allergy, compromised renal function, or uncontrolled thyroid disease require careful assessment before administration.

Optiray should be avoided in patients with a documented severe hypersensitivity to iodinated contrast agents, uncontrolled hyperthyroidism, or those with severe renal impairment (eGFR <30 mL/min/1.73 m²) unless the diagnostic benefit justifies the risk. Clinicians must evaluate each patient’s medical history before use.